These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29609830)

  • 1. Safety data and withdrawal of hepatotoxic drugs.
    Babai S; Auclert L; Le-Louët H
    Therapie; 2021; 76(6):715-723. PubMed ID: 29609830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use.
    Marquez L; Raheja R; Chan-Liston M; Marcinak J; Estilo A; Pineda Salgado L; Jiang J; Chang C; Beninger P
    Drug Saf; 2024 Jan; 47(1):1-22. PubMed ID: 37874451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience.
    Goldkind L; Laine L
    Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):213-20. PubMed ID: 16456879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury.
    Chen M; Borlak J; Tong W
    Hepatology; 2013 Jul; 58(1):388-96. PubMed ID: 23258593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges.
    Senior JR
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S9-17. PubMed ID: 25352324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.
    Suzuki A; Andrade RJ; Bjornsson E; Lucena MI; Lee WM; Yuen NA; Hunt CM; Freston JW
    Drug Saf; 2010 Jun; 33(6):503-22. PubMed ID: 20486732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review.
    Dirven H; Vist GE; Bandhakavi S; Mehta J; Fitch SE; Pound P; Ram R; Kincaid B; Leenaars CHC; Chen M; Wright RA; Tsaioun K
    Sci Rep; 2021 Mar; 11(1):6403. PubMed ID: 33737635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs.
    Shimizu Y; Sasaki T; Takeshita JI; Watanabe M; Shizu R; Hosaka T; Yoshinari K
    PLoS One; 2021; 16(6):e0253855. PubMed ID: 34170966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA-approved drug labeling for the study of drug-induced liver injury.
    Chen M; Vijay V; Shi Q; Liu Z; Fang H; Tong W
    Drug Discov Today; 2011 Aug; 16(15-16):697-703. PubMed ID: 21624500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury
    Rana P; Aleo MD; Wen X; Kogut S
    Acta Pharm Sin B; 2021 Dec; 11(12):3857-3868. PubMed ID: 35024312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using an Automated Algorithm to Identify Potential Drug-Induced Liver Injury Cases in a Pharmacovigilance Database.
    Pineda Salgado L; Gupta R; Jan M; Turkoglu O; Estilo A; George V; Rahman MI
    Adv Ther; 2021 Sep; 38(9):4709-4721. PubMed ID: 34319549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Battery of
    Rathman J; Yang C; Ribeiro JV; Mostrag A; Thakkar S; Tong W; Hobocienski B; Sacher O; Magdziarz T; Bienfait B
    Chem Res Toxicol; 2021 Feb; 34(2):601-615. PubMed ID: 33356149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatotoxicity by Drugs: The Most Common Implicated Agents.
    Björnsson ES
    Int J Mol Sci; 2016 Feb; 17(2):224. PubMed ID: 26861310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current challenges and controversies in drug-induced liver injury.
    Corsini A; Ganey P; Ju C; Kaplowitz N; Pessayre D; Roth R; Watkins PB; Albassam M; Liu B; Stancic S; Suter L; Bortolini M
    Drug Saf; 2012 Dec; 35(12):1099-117. PubMed ID: 23137150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human liver organoid screening platform for DILI risk prediction.
    Zhang CJ; Meyer SR; O'Meara MJ; Huang S; Capeling MM; Ferrer-Torres D; Childs CJ; Spence JR; Fontana RJ; Sexton JZ
    J Hepatol; 2023 May; 78(5):998-1006. PubMed ID: 36738840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high content screening assay to predict human drug-induced liver injury during drug discovery.
    Persson M; Løye AF; Mow T; Hornberg JJ
    J Pharmacol Toxicol Methods; 2013; 68(3):302-13. PubMed ID: 23933113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting and preventing acute drug-induced liver injury: what's new in 2010?
    Liss G; Rattan S; Lewis JH
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1047-61. PubMed ID: 20615079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties.
    Yucha RW; He K; Shi Q; Cai L; Nakashita Y; Xia CQ; Liao M
    Toxicol Sci; 2017 Jun; 157(2):487-499. PubMed ID: 28369588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.